Repare Therapeutics Inc.
RPTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | -$0 | -$0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 4,548% | – | – | – |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | 100% | 100% | – | – |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 29.9% | -7,610.4% | – | – |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 28% | -6,697.6% | – | – |
| EPS Diluted | 0.08 | -0.39 | -0.71 | -0.67 |
| % Growth | 120.5% | 45.1% | -6% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |